Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus

NCT04400994 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT04400994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 20, 2020
Completion date
June 30, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pemphigus